abiraterone acetate

Immunotherapy for GU Ca: A primer for urologistsThis article discusses the current status and potential future developments in immunotherapy for genitourinary malignancies with insights from urologic oncology specialists Hyung L. Kim, MD, and Daniel P. Petrylak, MD.
Assay predicts outcomes in men taking mCRPC agentExpression of androgen receptor splice variant 7 (AR-V7) in whole blood predicts worse cancer-related outcomes in patients with metastatic castration-resistant prostate cancer who are treated with abiraterone acetate (ZYTIGA).
Uro Pipeline: Trial launched for drugs' use in metastatic, hormone-sensitive PCaA novel oral TRT agent, bladder control system, and localized prostate cancer agent are among other treatments in the pipeline discussed in this round-up.
Concomitant Ra 223, abiraterone found safe, effectiveRadium 223 dichloride (Ra 223 [Xofigo]) can be safely combined with abiraterone acetate (ZYTIGA) for the treatment of patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases, and appears to result in decreased bone pain and improved quality of life, according to the interim results of an open-label prospective study known as eRADicAte.
FDA approves label update for advanced PCa treatmentFinal analysis of a phase III trial shows abiraterone acetate (ZYTIGA) plus prednisone extended overall survival compared to placebo plus prednisone in chemotherapy-naive men with mCRPC.
FDA approves label update for ZytigaFDA has approved label update for abiraterone acetate (Zytiga, Janssen) in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
FDA drug approvals-March 2015FDA actions in brief, breakthrough designation, recommended for approval, priority review, fast-track designations
Best of GU Cancers 2015: Dr. Thrasher’s picks and moreNew, large-scale studies on active surveillance, IMRT complications, and robotic versus open prostatectomy were among the highlights of this year’s Genitourinary Cancers Symposium.
January 2015 Product Preview: FDA committee recommends approval of complicated UTI agentDrugs and devices in the pipeline from Actavis, Genomic Health, Lipella Pharmaceuticals, Polaris Group, Innocrin Pharmaceuticals, OncoGenex Pharmaceuticals, Heat Biologics, Repros Therapeutics, and Sophiris Bio.
Second mCRPC agent shows significant benefit pre-chemoAbiraterone acetate (ZYTIGA) as therapy for chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) improved overall survival by a statistically significant 19% compared with placebo in the final analysis of the phase III COU-AA-302 clinical trial.